PCR检测HPV—18DNA

采用聚合酶链式反应（ＰＣＲ）技术,对ＨＰＶ－１８序列中引物ＨＰ１、ＨＰ２之间的片段（Ｆ）进行扩增,通过两组阴、阳性对照实验证明扩增片段的特异性。用不同Ｍｇ＾＋＋浓度的缓冲系统进行ＰＣＲ反应发现,缓冲系统中Ｍｇ＾＋＋浓度高低是影响ＨＰＶ－１８／ＨＰ１、ＨＰ２特异扩增的重要因素,高浓度Ｍｇ＾＋＋导致扩增特异性降低。对１７例宫颈癌组织ＤＮＡ进行ＰＣＲ检测,有９例检出Ｆ出段,其检出率是５３％,为ＨＰＶ－１     

巢－PCR分型检测人乳头状瘤病毒同源序列

采用Ｌ１通用引物ＭＹ１１／９介导聚合酶链反应,（ＰＣＲ）,从人生殖道疣,癌组织中扩增人乳头状瘤病毒（ＨＰＶ）同源序列得３９４－５５２ｂｐＤＮＡ片段,再以内引物ＧＰ５／６介导第二次扩增得１３９－１５４ｂｐ片段,然后根据ＲｓａＩ酶切扩增片段的电泳图谱来分出ＨＰＶ型别,无需特异型别的探针进行分子杂交,３５例宫颈癌和３０例生殖器疣ＨＰＶ同源序列检出率分别为８５．７５％和９６％;１２例卵巢腺癌检出ＨＰＶ同源     

抗原捕获聚合酶链式反应（AC－PCR）直接分型检测单纯疱疹病毒

用抗单纯疱疹病毒（ＨＳＶ）型共同性ｇＣ和ｇＤ羊克隆抗体（ＭｃＡｂ）,包被即Ｅｐｐｅｎｄｏｒｆ管,捕捉ＨＳＶ,同时加入３个引物：一个是ＨＳＶ─１／ＨＳＶ─２型共同性上游引物,另两个分别是ＨＳＶ─１和ＨＳＶ─２型特异性下游引物。借此建立了能直接分型检测ＨＳＶ的抗原捕获聚合酶链式反应（ＡＣ─ＰＣＲ）。ＨＳＶ─１的扩增产物为４７７ｂｐ,ＨＳＶ─２的为３９９ｂｐ两型病毒经ＡＣ─ＰＣＲ扩增后产生分子量不同的ＤＮＡ片段,致使ＡＣ─ＰＣＲ能直接分型检测ＨＳＶ。ＨＳＶ─１和ＨＳＶ─２扩增产物的克隆和序列分析表明,本方法特异性好。用本法检测Ｂａｌｂ／ｃ幼鼠中枢神经系统ＨＳＶ感染的脑标本,进一步证实本方法不仅敏感、特异,而且分型准确。     

用PCR扩增和克隆马立克氏病病毒糖蛋白D基因

用ＰＣＲ技术,从ＧＡ株马立克氏病病毒（ＭＤＶ）感染的成纤维细胞（ＧＥＦ）基因组ＤＮＡ中扩增出ＭＤＶ糖蛋白Ｄ（ｇＤ）抗原基因片段的约１３００ｂｐ编码序列,将该ｐｃＲ扩增的产物于ＥｃｏＲＩ和Ｋｐｎｌ位点克隆到ｐＵＣ１８质粒载体中,在以ｄｉｇｏｘｉｇｅｎｉｎ（ｄｉｇ）标记的ｇＤＰＣＲ产物作为探针,进行原位杂交初步筛选到阳性重组质粒克隆,再根据酶切分析筛选到含ＭＤＶｇＤ基因的重组质粒ｐ１８ＭｇＤ。将ｐ１８ＭｇＤ质粒ＤＮＡ用ｄｉｇ标记后,在Ｓｏｕｔｈｅｒｎｂｌｏｔ中,该探针能识别ＭＤＶ基因组ＤＮＡ的ＢａｍＨＩ－Ａ克隆中的Ａ片段ＤＮＡ。酶切位点分析表明,该ｇＤ克隆也和已发表的ＭＤＶ的ＲＢＩＢ株ｇＤ一样,不含有ＥｃｏＲⅠ、ＨｉｎｄⅢ、ＰｓｔⅠ、ＳｍａⅠ、ｐｖｕⅡ等酶切位点。证明该重组质粒是ＭＤＶｇＤ克隆。     

抗原捕获聚合酶链式反应（AC—PCR）直接分型检测单纯疱疹病毒

用抗单纯疱疹病毒（ＨＳＶ）型共同性ｇＣ和ｇＤ单克隆抗体（ＭｃＡｂ）,包被Ｅｐｐｅｎｄｏｒｆ管,捕捉ＨＳＶ,同时加入３个引物：一个是ＨＳＶ－１／ＨＳＶ－型共同性上游引物,另两个分别是ＨＳＶ－１和ＨＳＶ－２型特异性下游引物。借此建立了能直接分型检测ＨＳＶ的抗原捕获聚合酶链式反应（ＡＣ－ＰＣＲ）。ＨＳＶ－１的扩增产物为４７７ｂｐ,ＨＳＶ－２的为３９９ｂｐ,两型病毒经ＡＣ－ＰＣＲ扩增后产生分子量不同的ＤＮ     

多聚酶链反应检测宫颈HPV感染及分型的研究

本文应用ＰＣＲ技术检测２ｌ２例临床宫颈标本的ＨＰＶ－６、ｌｌ、１６、１８型特异性核酸序列。结果发现ＨＰＶ－ＤＮＡ的阳性率：宫颈癌组为６２．５％（２５／４０）．慢性宫颈炎为５７％（８１／１４２）,正常宫颈对照组为２０％（６／３０）,Ｐ＜０．００１,提示ＨＰＶ的感染与宫颈炎、宫颈癌有关。同时分型结果显示：ＨＰＶ－６、１６、１８型与宫颈炎相关,１６型与宫颈癌密切相关,且ＨＰＶ不同型别的混合感染在宫颈中普遍存在（３１．３％）。成年女性各年龄组间ＨＰＶ的感染率并无明显差异（Ｐ＞０．０５）。     

鼻咽癌中Epetein－Barr病毒基因结构特点

鼻咽癌中感染的ＥＢＶ以潜伏态存在,只有少数基因得到表达。我们从分子生物学水平研究其潜伏机制。已知ＢＺＬＦｌ基因和ＢａｍＨＩＥＺ片段内部分基因对ＥＢＶ的复制激活起关键作用。我们用体外基因扩增（ＰＣＲ）法扩增ＢＺＬＦｌ基因外显子－１序列,并用序列分析法研究了该基因结构特点。此外,检测了ＢａｍＨＩＥＺ片段内缺失,结果发现２１例鼻咽癌（ＮＰＣ）组织中,ｌｌ例有ＢａｍＨＩＥＺ片段内缺失,长２．９９ｋｂ,与潜伏态存在的ＲａｊｉＥＢＶ类似。提示鼻咽癌小的ＥＢＶ以潜伏态存在,与ＮＰＣ发病有关。     

应用套式PCR对恶性卡他热病毒在不同动物体内变异的研究

应用本实验建立的三组套式ＰＣＲ（ＰＣＲ１、２、３）和一组以前报道的套式ＰＣＲ（ＰＣＲ４）,对５９份外周血淋巴细胞（ＰＢＬ）ＤＮＡ样品进行了恶性卡他热病毒（Ｍａｌｉｇｎａｎｔｃａｔａｒｒｈａｌｆｅｖｅｒｖｉｒｕｓ,ＭＣＦＶ）核酸序列的检测。这些样品来自５１只羊,以及与羊接触而发病的６头牛和２只鹿。除ＰＣＲ４外,其它三组ＰＣＲ都能扩增现有４个角马型ＭＣＦＶ分离株。有６只羊在４组ＰＣＲ中都呈阴性,其余５３份样品经ＰＣＲ４检测均呈阳性。ＰＣＲ１只能从４５只羊体检出ＭＣＦＶＤＮＡ,未能从牛和鹿体检出病毒ＤＮＡ。ＰＣＲ２检测的所有样品均呈阴性。在ＰＣＲ３扩增中,除２头牛外,其它５１份样品均呈阳性。通过Ｓｏｕｔｈｅｒｎ杂交和限制性酶切分析,对ＰＣＲ１－４产物的特异性进行了鉴定。此外,敏感性实验表明,四组ＰＣＲ的差异也不明显。因此,本实验结果说明ＭＣＦＶ基因组在不同种动物之间发生了变异,羊体内的变异株可能是导致其它反刍动物发病的病原     

人乳头瘤病毒6b型晚期蛋白L_2免疫反应表位的确定

人乳头瘤病毒（ＨＰＶ）含有２个晚期开放读码框（ＯＲＦ）,Ｌ＿２ＯＲＦ编码的蛋白具有型特异性。本研究用能表达产生完整ＨＰＶ６ｂＬ＿２蛋白的质粒ｐ６ｂＬ＿２ＮＸ,采取核酸外切酶Ⅲ定向连续次级克隆的方法,制备了一系列一端逐渐删切的ＤＮＡ片段,诱生一组从Ｃ端至Ｎ瑞依次减少的Ｌ＿２蛋白与相应血清作免疫印迹实验,最小的仍保持阳性反应的多肽即含有抗原表位,实验结果ＨＰＶ６ｂＬ＿２蛋白的核酸编码区位于５４８１－５５０６之间,其相应氨基酸序列是ＥＰＧＩＮＰＴＱ。     

猪圆环病毒2型ORF2基因序列分析及真核表达载体的构建

根据ＧｅｎＢａｎｋ中猪圆环病毒２型（ＰＣＶ－２）ＯＲＦ２基因序列,设计一　对引物,应用ＰＣＲ从疑患断奶仔猪多系统消耗综合症（ＰＭＷＳ）的死亡仔猪组织病料中扩增出ＯＲＦ　２全基因（７０２ｂｐ）。将此片段克隆入ｐＧＥＭ－Ｔ　ｅａｓｙ载体,筛选获得重组质粒ｐＴＯＲＦ２,并对此质　粒中的插入序列进行了测序分析,结果表明本试验克隆的ＯＲＦ２与美国ＰＣＶ－２分离株ＡＦ２６４０３９　的核苷酸及氨基酸序列同源性均达到１００％,与其他ＰＣＶ－２毒株同源性分别为９２．３％～９８．　６％和　９２．３％～９６．６％。重组质粒ｐＴＯＲＦ２经　Ｂａｍ　Ｈ　Ｉ、Ｅｃｏ　Ｒ　Ｖ双酶切,回收ＯＲＦ２基因,转　移入真　核表达载体ｐＳｅｃＴａｇ２／ＨｙｇｒｏＢ的相应酶切位点之间,构建成重组质粒ｐＳｅｃＴａｇＯＲＦ２。此重组表　达载体的构建成功为进一步研究ＯＲＦ２编码蛋白的生物学活性及建立ＰＣＶ诊断试剂盒打下基础。     

宫颈癌中p53表达和病毒感染的研究

应用PCR对121例宫颈脱落细胞和组织分别检测HPV-16／18和HSV-2DNA。同时应用免疫组化S-P法检测76例宫颈组织中P53过度表达。结果发现,宫颈癌组织中HPV-16／18和HSV-2阳性率分别为61．3％和32．3％,慢性宫颈炎组HPV-16／18和HSV-2阳性率分别为22．5％和20．0％,与正常宫颈组比较均有显著性差异。宫颈癌中HPV-16／18和HSV-2混合感染率为16．1％。p53过度表达率在慢性宫颈炎、宫颈上皮内瘤变(CIN)、宫颈癌组织中呈梯度递增。另外,宫颈癌组织中P53过度表达与HPV-16／18、HSV-2的感染无相关性。提示：宫颈癌的发生与HPV-16／18关系密切,HSV-2可能与HPV-16／18协同作用导致宫颈癌的发生。宫颈组织中p53过度表达率与宫颈癌的进程有关,这在宫颈癌的防治方面有一定的临床意义。     

Prevalence of human papillomavirus genotypes in cervical cancer and precursor lesions

There are no data obtained in biopsy material on the prevalence of human papillomavirus (HPV) and HPV genotypes in Croatian women with cervical carcinoma and precursor lesions. Therefore, the prevalence of HPVand HPVgenotypes was investigated in archival material of cervical carcinoma and precursor lesions kept at Department of Pathology, School of Medicine, University of Rijeka. DNA was isolated from formalin fixed, paraffin embedded tissue, histologically classified as cervical intraepithelial neoplasia (CIN) III (n =43), squamous cell carcinoma (SCC) (n =54) and adenocarcinoma (ADC) (n =40). HPV testing was performed bypolimerase chain reaction (PCR) using generic and genotype specific primers. The prevalence of HPV DNA was 93.02%, 92.59%, and 92.5% in CIN III, SCC and ADC, respectively. In CIN III and SCC, HPV-16 was the most common high-risk genotype, identified in 65% and 52%, followed by HPV-18 in 22.5% and 28% of cases, respectively. HPV-18 showed a statistically significant prevalence in ADC (67.6%) as compared with SCC (chi(2)=9.924; p_ 0.01). Study results revealed a high prevalence of HPV-DNA in examined cervical lesions (>90%). HPV-16 predominated in SCC and HPV-18 in ADC. Single infection was more frequently present than multiple infections in all three histological groups.     

Presence of human papillomavirus genome in human tumor cell lines and cultured cells.

A series of 47 human carcinoma cell lines and their cultured cells were examined for human papillomavirus (HPV) genomes with the use of an HPV detection kit (DNA-RNA hybridization, mixed HPV DNA probe of types 6, 11, 16, 18, 31, 33 and 35). Four of 8 cases of mild dysplasia, 3 of 9 cases of severe dysplasia, 3 of 7 cases of carcinoma in situ, 3 of 15 cases of uterine carcinoma and 5 of 6 cases of condyloma acuminatum were shown to contain the HPV DNA genome in primary cultured cells, while HPV was not detected in the third-passage cells except for the three cases of large cell, nonkeratinizing squamous cell carcinoma. HPV was also not detected in such normal tissues as uterine cervical squamous epithelium, uterine cervical columnar epithelium and endometrium. The presence of HPV DNA genomes was detected consistently in the passages of three lines (SKG-II, HKMUS and HKTUS; large cell nonkeratinizing squamous cell carcinomas of the uterine cervix) with the use of the Southern Blot method (DNA-DNA hybridization, mixed HPV probe of types 6, 11, 16 and 18). HPV type 16 DNA was detected in HKTUS, and HPV type 18 DNA was found in SKG-II and HKMUS. The other 44 cell lines, including ovarian carcinoma, endometrial carcinoma, sarcoma, gastric cancer, pancreatic cancer and rectal cancer, were negative for the HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33 and HPV-35 genomes under stringent hybridization conditions.     

Heterografts of human cervical cancer. Characterization of papillomavirus genomes

Three new human cervical carcinoma xenografts was established from clinical tumor specimens of patients with I-II stages of disease. Growth characteristics of models are writing. Xenografts designated CC 9, 24 and 25 contain integrated DNA HPV, complemented DNA HPV-16. DNA CC 5 contain neither DNA HPV-16, nor DNA HPV-18.     

DNA sequences of human papillomavirus types 11, 16, and 18 in lesions of the uterine cervix in the west of Scotland.

Punch biopsy specimens of the cervix were examined both histologically and for the presence of human papillomavirus (HPV) DNA sequences. The presence of HPV DNA sequences was sought with the Southern blot technique using radioactively labelled HPV-6, 11, 16, and 18 DNA probes, both together and separately. Twenty six biopsy specimens were examined. Histological examination showed cervical intraepithelial neoplasia grade 2 or 3 in 16 specimens, viral changes (koilocytosis) in four, and inflammation or a normal appearance in three. Eleven specimens were negative for HPV DNA sequences, 10 contained HPV-16 DNA, four contained HPV-18 DNA, and one contained both HPV-18 and HPV-11 DNA. Episomal HPV-16 DNA was detected in one case of cervical intraepithelial neoplasia grade 3 and in five cases of cervical intraepithelial neoplasia grade 2/3 with koilocytosis; and episomal HPV-18 DNA was found in two specimens classed as cervical intraepithelial neoplasia grade 2/3, one of which also contained HPV-11 DNA, and in one specimen that showed viral changes alone. Integrated HPV DNA was found in six specimens (four with HPV-16 DNA and two with HPV-18 DNA), including two cases of chronically inflamed cervix with no histological evidence of viral infection or cervical intraepithelial neoplasia. Detection of viral DNA in early lesions may identify patients at risk of malignant progression. This is the first report of HPV-18 DNA in cervical intraepithelial neoplasia in Scotland.     

Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines.

Human cervical carcinoma cell lines that harbor human papillomavirus (HPV) have been reported to retain selectively and express HPV sequences which could encode viral E6 and E7 proteins. The potential importance of HPV E6 to tumors is suggested further by the observation that bovine papillomavirus (BPV) E6 can induce morphologic transformation of mouse cells in vitro. To identify HPV E6 protein, a polypeptide encoded by HPV-16 E6 was produced in a bacterial expression vector and used to raise antisera. The antisera specifically immunoprecipitated the predicted 18-kd protein in two human carcinoma cell lines known to express HPV-16 RNA and in mouse cells morphologically transformed by HPV-16 DNA. The 18-kd E6 protein was distinct from a previously identified HPV-16 E7 protein. The HPV-16 E6 antibodies were found to be type specific in that they did not recognize E6 protein in cells containing HPV-18 sequences and reacted weakly, if at all, to BPV E6 protein. The results demonstrate that human tumors containing HPV-16 DNA can express an E6 protein product. They are consistent with the hypothesis that E6 may contribute to the transformed phenotype in human cervical cancers that express this protein.     

A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms

BACKGROUND: Several human epithelial neoplasms are associated with high-risk strains of human papillomavirus (HPV) such as cervical, anorectal, and other carcinomas. For some tumor types the current therapeutic tools are only palliative. Conditionally replicative adenoviruses (CRAds) are promising antineoplastic agents, which also can trigger confined antitumor effects. METHODS: We constructed a series of CRAds driven by the upstream regulatory promoter region (URR) of an Asian-American variant of HPV-16, which contained different mutations at the E1A region (dl1015 and/or Delta24) and wild-type. All vectors were tested in vitro for viral replication and cytotoxicity. Viral DNA replication and E1A expression were also assessed by quantitative PCR. Finally, we confirmed the antitumoral efficacy of this vector in injected and non-injected xenotransplanted cervical tumors in a murine model for tumor regression and survival studies. RESULTS: A vector denominated Ad-URR/E1ADelta24 displayed a potent cytopathic effect associated with high selectivity for HPV+ cell lines. We found that the oncolytic effect of this CRAd was comparable to Ad-wt or Ad-Delta24, but this efficacy was significantly attenuated in HPV- cell lines, an effect that was contributed by the URR promoter. Ad-URR/E1ADelta24 was very effective to control tumor growth, in both, injected and non-injected tumors generated with two different HPV+ cell lines. CONCLUSIONS: CRAd Ad-URR/E1ADelta24 is a highly selective vector for HPV+ cell lines and tumors that preserves the oncolytic efficacy of Ad-wt and Ad-Delta24. Our preclinical data suggest that this vector may be useful and safe for the treatment of tumors induced by HPV, like cervical cancers.     

新疆维族妇女感染的HPV 型别分布的研究

目的:探讨人乳头瘤状病毒(Human papillomavirus,HPV)在新疆南部维族妇女人群中的型别分布情况。方法:以年龄在30-59岁的新疆伽师县夏普吐勒乡维吾尔族妇女人群为基础进行筛查,签署知情同意书后,采集受试者宫颈脱落细胞,利用PCR和基因芯片技术检测HPV DNA并分型。结果:共2473名妇女入选。HPV总的感染率为9.1%,高危型中HPV-16的感染率最高为6.9%,其他高危型的感染率从高到低依次为:HPV-59、HPV-56、HPV-18、HPV-33、HPV-58、HPV-51、HPV-31、HPV-45、HPV-52、HPV-68、HPV-35、HPV-39。低危型中HPV11感染率最高,其他低危型的感染率从高到低依次为HPV-42、HPV-43、HPV-6、HPV-53、HPV-66、HPV-73。HPV-44、-83、-MM4没检测到。多重感染率为34.2%。结论:新疆维吾尔族妇女人群中以HPV16感染为主,其次为HPV59、56、18、33等。HPV59可能是新疆维吾尔族妇女较易感染的类型。体现了新疆维吾尔族妇女感染HPV的特殊性。     

HLA DOA1 and DOB1 loci in Honduran women with cervical dysplasia and invasive cervical carcinoma and their relationship to human papillomavirus infection.

Molecular and epidemiological studies have demonstrated that certain types of human papillomavirus (HPV), mainly HPV-16 and HPV-18, are the primary causes of cervical cancer and its precursor lesions; there is now evidence for a clear association with specific HLA class I and class II loci contributing independently to the expression of cervical cancer. Among Honduran women carcinoma of the cervix is the most common type of cancer, and infections with high-risk HPV types are highly prevalent. To study the interactive role of viral-host genetics, we performed PCR amplification of DNA and sequence-specific oligonucleotide probe typing on cervical scrapes from 49 women [24 with cervical intraepithelial neoplasia stage III or cervical cancer (severe cases) and 25 with stage I or II cervical intraepithelial neoplasia (mild cases)] and 75 control subjects to look for possible associations between HPV and HLA class II DQA1 and DQB1 alleles in the development of dysplasias and invasive cancer. This analysis revealed a predominance of HLA-DQA1*0301 among severe-case patients [relative risk (RR) = 3.45, p = 0.008), whereas DQA1*0501 was negatively associated (RR = 0.30, p = 0.03), suggesting a protective effect of this allele. HPV typing showed a decreased relative risk among the HPV-16 or HPV-18 carrying patients and other HPV-related positive patients in the presence of DQB1*0602 compared with positive control subjects (p = 0.04). No statistically significant allele frequency difference was observed between mild dysplasia cases and control subjects. The results suggest that DQA1*03011, which is in linkage desequilibrium with all HLA-DR4 alleles, confers an increased risk for severe cervical dysplasia and invasive cancer, whereas DQA1*0501, which is in several DR52 haplotypes, has a protective effect. Furthermore, specific HLA-DQB1 sequences may be important in determining the immune response to HPV peptides and may affect the risk for cervical cancer after HPV infection in mestizo Honduran women.